Compare AbCellera Biologics Inc (ABCL) vs Zillow Group Inc Class A (ZG) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Zillow Group (ZG) trades at $32.69, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported revenue of $2.58 billion for 2025 with a net income of $23 million, marking a return to profitability after losses in prior years. Recent news is dominated by multiple securities class action lawsuits alleging anticompetitive conduct, creating significant headline risk.

The investment outlook is clouded by legal overhangs despite positive earnings beats and a consensus analyst price target of $57.80 implying substantial upside. Key risks include the outcome of litigation and the sustainability of recent margin improvements. The high P/E ratio of 131.8 suggests growth expectations are already priced in, demanding flawless execution.